Expression of tumor-associated macrophages and vascular endothelial growth factor correlates with poor prognosis of peripheral T-cell lymphoma, not otherwise specified

Leukemia and Lymphoma

Volumn 52, Issue 1, 2011, Pages 46-52

  Zhang, Wei ^a   Wang, Liang ^b   Zhou, Daobin ^a   Cui, Quancai ^a   Zhao, Dachun ^a   Wu, Yongji ^a  

^a PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

^b SUN YAT SEN UNIVERSITY   (China)

Author keywords

international prognostic index IPI; not otherwise specified PTCL NOS; overall survival OS; Peripheral T cell lymphoma; tumor associated macrophage TAM; vascular endothelial growth factor VEGF

Indexed keywords

CD68 ANTIGEN; CISPLATIN; DEXAMETHASONE; ETOPOSIDE; FLUDARABINE; GEMCITABINE; IFOSFAMIDE; MESNA; MITOXANTRONE; VASCULOTROPIN;

ADOLESCENT; ADULT; AGED; ARTICLE; BONE MARROW; CANCER INVASION; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; FEMALE; HUMAN; HUMAN TISSUE; INTERNATIONAL PROGNOSTIC INDEX; MALE; OVERALL SURVIVAL; PERIPHERAL T CELL LYMPHOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; SCORING SYSTEM; SURVIVAL TIME; T CELL LYMPHOMA; TREATMENT RESPONSE; TUMOR ASSOCIATED LEUKOCYTE;

ADOLESCENT; ADULT; AGED; ANTIGENS, CD; ANTIGENS, DIFFERENTIATION, MYELOMONOCYTIC; BONE MARROW; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOENZYME TECHNIQUES; LYMPHOMA, T-CELL, PERIPHERAL; MACROPHAGES; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; PROGNOSIS; RISK FACTORS; SURVIVAL RATE; VASCULAR ENDOTHELIAL GROWTH FACTOR A; YOUNG ADULT;

EID: 78651291664     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2010.529204     Document Type: Article

References (15)

1. Isaacson PG. The current status of lymphoma classification. Br J Haematol 2000;109:258-266.
2. Pollard JW. Tumor-educated macrophages promote tumor progression and metastasis. Nat Rev Cancer 2004;4:71-78.
3. Weigert A, Sekar D, Brune B. Tumor-associated macrophages as targets for tumor immunotherapy. Immunotherapy 2009;1: 83-95.
4. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med 2003;9:669-676.
5. Jørgensen JM, Sørensen FB, Bendix K, et al. Expression level, tissue distribution pattern, and prognostic impact of vascular endothelial growth factors VEGF and VEGF-C and their receptors Flt-1, KDR, and Flt-4 in different subtypes of non-Hodgkin lymphomas. Leuk Lymphoma 2009;50:1647-1660.
6. Delsol G. 2008 WHO lymphoma classification. Ann Pathol 2008;28 Spec No 1: S20-S24.
7. Canioni D, Salles G, Mounier N, et al. High numbers of tumor-associated macrophages have an adverse prognostic value that can be circumvented by rituximab in patients with follicular lymphoma enrolled onto the GELA-GOELAMS FL-2000 trial. J Clin Oncol 2008;26:440-446.
8. Oda Y, Yamamoto H, Tamiya S, et al. CXCR4 and VEGF expression in the primary site and the metastatic site of human osteosarcoma: analysis within a group of patients, all of whom developed lung metastasis. Mod Pathol 2006;19:738-745.
9. Mantovani A, Allavena P, Sica A. Tumor-associated macro-phages as a prototypic type II polarized phagocyte population: role in tumor progression. Eur J Cancer 2004; 40:1660-1667.
10. Zheng Y, Cai Z, Wang S, et al. Macrophages are an abundant component of myeloma microenvironment and protect myeloma cells from chemotherapy drug-induced apoptosis. Blood 2009;114:3625-3628.
11. Takahashi R, Tana S, Kitadai Y, et al. Expression of vascular endothelial growth factor and angiogenesis in gastrointestinal stromal tumor of the stomach. J Oncol 2003;64:266-274.
12. Knowles HJ, Harris AL. Macrophages and the hypoxic tumor microenvironment. Front Biosci 2007;12:4298-4314.
13. Hermans J, Krol AD, van Groningen K. International Prognostic Index for aggressive non-Hodgkin's lymphoma is valid for all malignancy grades. Blood 1995;86:1460-1463.
14. Morabito F, Gallamini A, Stelitano C, et al. Clinical relevance of immunophenotype in a retrospective comparative study of 297 peripheral T-cell lymphomas, unspecified, and 496 diffuse large B-cell lymphoma: experience of the Intergruppo Italino Linformi. Cancer 2004;101:1601-1608.
15. Bruns I, Fox F, Reinecke R, et al. Complete remission in a patient with relapsed angioimmunoblastic T-cell lymphoma following treatment with bevacizumab. Leukemia 2005;19: 1993-1995.